Beclomethasone nasal spray doesn't increase IOP

Beclomethasone nasal spray doesn't increase IOP in patients with ocular hypertension and primary open-angle glaucoma, reveals a study in the Journal of Glaucoma.

Beclomethasone nasal spray doesn't increase IOP in patients with ocular hypertension and primary open-angle glaucoma, reveals a study in the Journal of Glaucoma.

Dr D. Yuen et al., Department of Ophthalmology and Visual Sciences, Toronto Western Hospital, Toronto, Canada, completed a randomized, double-masked, controlled trial on 19 patients who were randomized to twice-daily beclomethasone versus placebo saline nasal spray.

Four study visits were conducted: baseline, a weeks 2, 4, 6 after starting the nasal spray. The primary outcome measure was IOP and secondary measures were visual acuity, anterior segment changes, patient reported side effects and compliance.

There were no statistically significant differences in baseline characteristics, IOP at each study visit, or change in IOP between the two groups. The mean change in IOP from baseline was +0.50±1.52 versus +0.70±1.44 mm Hg in the steroid and saline nasal spray groups, respectively at the six-week follow-up, concluding that beclomethasone nasal spray does not affect IOP in OHT and POAG patients.

To view the abstract please click here.

Related Videos
Disrupting the glaucoma treatment paradigm with novel femtosecond laser from ViaLase
2-year data in contralateral eye evaluation gives edge to iStent inject over Hydrus stent
Should endocyclophotocoagulation be considered part of MIGS? Mr Ratnarajan delves in
Investigating the effects of canaloplasty on corneal epithelium
POAG study hope to open a new avenue for therapies that are for helping treat patients that develop primary open angle glaucoma
Gonio-intervention robot-assisted glaucoma surgical procedure offers high precision
Related Content
© 2023 MJH Life Sciences

All rights reserved.